Focus Areas

Prevention, Diagnosis & Treatment

Bayer is committed to meeting the needs of patients in our therapeutic areas of focus, including cardiovascular disease, pulmonary hypertension, hematology, oncology, and women’s healthcare. Bayer’s brands treat and prevent conditions to improve quality of life. (Bayer’s U.S. R&D program supports some of Bayer’s more broad global focus areas).



Bayer’s U.S. oncology expertise is deep and wide. In the U.S., Bayer currently markets treatments for prostate, colorectal, follicular lymphoma, kidney, liver, and thyroid cancers as well as a precision treatment for NTRK fusions, which are found in more than 25 solid tumor types, including pediatrics cancers. Bayer oncology seeks to address gaps in treatment by developing new therapeutic options that improve patient benefit and their corresponding health outcomes.

Women’s health

Empowering women to make a conscious decision on whether and when to have children has decisively strengthened women’s roles in society. Thanks to modern hormonal contraceptives ranging from pills to intrauterine devices, couples today can better plan their families and experience sexuality with the security in knowing that pregnancy is prevented.



Bayer has numerous compounds for hemophilia A currently on the market and continues to invest in the development of innovative treatments and solutions for people with hemophilia across the world. This focus on advancing hemophilia care and treatment show our commitment to the community.

Cardiovascular and Renal

Bayer’s history is steeped in cardiovascular care, and Bayer continues to develop products that may be of benefit for patients with various cardiovascular challenges. In the case of chronic kidney disease, kidney malfunction can have a detrimental effect on the cardiovascular system, so Bayer is exploring solutions that impact kidney health.

Pulmonary hypertension

In the area of Pulmonary Hypertension, scientists at Bayer discovered direct stimulators of soluble guanylate cyclase stimulators (sGC), a new way to widen the blood vessels, to lower blood pressure in the lungs and relieve the heart. Bayer’s compound became the first member of this distinct class of medicines and the first drug therapy to be approved in two forms of pulmonary hypertension. Its distinct mode of action has the potential to overcome a number of limitations of previously approved treatments for pulmonary arterial hypertension (PAH) and it is the first drug therapy to become available for another type of PH, inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment.


Being diagnosed through radiology is often the first step in a patient’s journey. These helpful diagnostic tools give healthcare professionals control to properly identify an ailment and know if treatment is working. Bayer provides radiologists with a portfolio of diagnostic imaging products and services along the radiology workflow and engages collaboratively with original equipment manufacturers (OEMs) of diagnostic imaging scanners and healthcare IT partners.


Bayer has been committed to radiology for more than 100 years and continues to partner with radiologists to guide diagnostic care. Explore our radiology solutions.